Company Description
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.
Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products.
The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025.
The company was founded in 2019 and is based in Naples, Florida.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Andrew Regan |
Contact Details
Address: 4581 Tamiami Trail North, Suite 200 Naples, Florida 34103 United States | |
| Phone | 646 491 9132 |
| Website | conduitpharma.com |
Stock Details
| Ticker Symbol | CDT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001896212 |
| CUSIP Number | 20678X304 |
| ISIN Number | US20678X5023 |
| Employer ID | 87-3272543 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrew Regan | Founder, Chief Executive Officer and Director |
| James Bligh | Co-Founder, Chief Financial Officer and Director |
| Dr. Joanne M. Holland | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | 8-K | Current Report |
| Apr 22, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 15, 2026 | 10-K | Annual Report |
| Apr 2, 2026 | 424B5 | Filing |
| Apr 1, 2026 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 30, 2026 | SCHEDULE 13D | Filing |
| Mar 25, 2026 | 8-K | Current Report |
| Mar 18, 2026 | 8-K | Current Report |
| Mar 9, 2026 | 8-K | Current Report |
| Mar 6, 2026 | DEF 14A | Other definitive proxy statements |